leukotriene


Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.

leu·ko·tri·ene

 (lo͞o′kə-trī′ēn)
n.
Any of several lipid compounds that contain 20 carbon atoms, are related to prostaglandins, and mediate the inflammatory response.

[leuko(cyte) + triene, a compound containing three double bonds (tri- + -ene).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

leukotriene

(ˌluːkəʊˈtraɪiːn)
n
(Biochemistry) one of a class of products of metabolic conversion of arachidonic acid; the active constituents of slow-reacting substance, responsible for bronchial constriction, contraction of smooth muscle, and inflammatory processes
[C20: from leukocyte, in which they were discovered + triene from the conjugated triene unit that they contain]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

leu•ko•tri•ene

or leu•co•tri•ene

(ˌlu kəˈtraɪ in)

n.
a lipid, C20H30O3, produced by white blood cells in an immune response to antigens, that contributes to allergic asthma and inflammatory reactions.
[1975–80; leuko- + triene (see tri-, -ene)]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
References in periodicals archive ?
Leukotriene B4 and C4 in cerebrospinal fluid from children with meningitis and febrile seizures.
Target: Rights to the leukotriene C4 synthase inhibitor programme (OX-CLI project)
Discriminant analysis revealed that these markers included three metabolites (dodecanal, 8-hydroxyguanosine, and leukotriene C4), three proteins (a1-antitrypsin, IgA-uromodulin complex, and galactose-deficient IgA1), and heparan sulfate (Box 2, Figure 1).
INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs.
Taken orally, zileuton inhibits the 5-LO enzyme, which would otherwise catalyze the formation of leukotrienes from arachidonic acid.
Omega-6 fatty acids are commonly thought to be pro-inflammatory, because linoleic acid (the major omega-3 fatty acid in the diet) is converted in part to arachidonic acid, which is a precursor for pro-inflammatory eicosanoids such as prostaglandin E2, leukotriene B4, and thromboxane A2.
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression.
Montelukast inhibits the actions of leukotriene D4 (LTD4) by reversibly binding on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes.
Akari's lead drug candidate, Coversin, is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.
It is demonstrated that montelukast, a cysteinyl leukotriene receptor 1 antagonist, alleviates WAS-induced bladder damage by inhibiting mast cell activation and preserve the urothelial mucous layer through its antioxidant effects.
When the animals were 12 months old, the equivalent of age 60 in humans, they were treated with zileuton, a drug that inhibits leukotriene formation by blocking the 5-lipoxygenase enzyme.
Akari is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by the dysregulation of complement C5 and/or leukotriene B4 (LTB4).